Literature DB >> 10398545

Hypoglycemia is the limiting factor in the management of diabetes.

P E Cryer1.   

Abstract

Hypoglycemia is the limiting factor, both conceptually and in practice, in the management of diabetes mellitus. While the long-term goal of diabetes research must remain the cure and the prevention of the disease and reasonable near-term goals might include perfect insulin replacement or prevention of complications despite ongoing hyperglycemia, the most pressing short-term goal for people with diabetes would seem to be insight leading to strategies that effectively minimize the risk of hypoglycemia and thus permit low-risk glycemic control. Having reviewed the field in detail recently, the author offers his personal views of the key questions - concerning the physiology of glucose counterregulation, its pathophysiology in diabetes, and hypoglycemia in diabetes - that, if answered, might lead to a reduced risk of iatrogenic hypoglycemia in people with diabetes. The overriding question is: How can we learn to replace insulin more perfectly, prevent, correct or compensate for compromised glucose counterregulation, or both? Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10398545     DOI: 10.1002/(sici)1520-7560(199901/02)15:1<42::aid-dmrr1>3.0.co;2-b

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  44 in total

1.  System-level control to optimize glucagon counterregulation by switch-off of α-cell suppressing signals in β-cell deficiency.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  J Diabetes Sci Technol       Date:  2009-01

2.  Multilevel model of type 1 diabetes mellitus patients for model-based glucose controllers.

Authors:  Winston Garcia-Gabin; Elling W Jacobsen
Journal:  J Diabetes Sci Technol       Date:  2013-01-01

3.  Differential changes in brain glucose metabolism during hypoglycaemia accompany loss of hypoglycaemia awareness in men with type 1 diabetes mellitus. An [11C]-3-O-methyl-D-glucose PET study.

Authors:  E M Bingham; J T Dunn; D Smith; J Sutcliffe-Goulden; L J Reed; P K Marsden; S A Amiel
Journal:  Diabetologia       Date:  2005-09-06       Impact factor: 10.122

4.  Models of glucagon secretion, their application to the analysis of the defects in glucagon counterregulation and potential extension to approximate glucagon action.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

Review 5.  Emotional and quality-of-life aspects of diabetes management.

Authors:  William H Polonsky
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

6.  Reliability of Trained Dogs to Alert to Hypoglycemia in Patients With Type 1 Diabetes.

Authors:  Evan A Los; Katrina L Ramsey; Ines Guttmann-Bauman; Andrew J Ahmann
Journal:  J Diabetes Sci Technol       Date:  2016-08-28

7.  Subconjunctivally Implanted Hydrogels for Sustained Insulin Release to Reduce Retinal Cell Apoptosis in Diabetic Rats.

Authors:  Hisanori Imai; Gauri P Misra; Linfeng Wu; Dileep R Janagam; Thomas W Gardner; Tao L Lowe
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

8.  A novel method for assessing insulin dose adjustments by patients with diabetes.

Authors:  Carine Choleau; A Michael Albisser; Avner Bar-Hen; Hélène Bihan; Catherine Campinos; Zohra Gherbi; Rached Jomaa; Mammoud Aich; Régis Cohen; Gérard Reach
Journal:  J Diabetes Sci Technol       Date:  2007-01

9.  Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina.

Authors:  Gauri P Misra; Ravi S J Singh; Tomas S Aleman; Samuel G Jacobson; Thomas W Gardner; Tao L Lowe
Journal:  Biomaterials       Date:  2009-08-25       Impact factor: 12.479

10.  Amplification of pulsatile glucagon counterregulation by switch-off of alpha-cell-suppressing signals in streptozotocin-treated rats.

Authors:  Leon S Farhy; Zhongmin Du; Qiang Zeng; Paula P Veldhuis; Michael L Johnson; Kenneth L Brayman; Anthony L McCall
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-24       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.